Campbell Soup Co. (CPB) Stock Price Today
Aura AI Summary
Key Stats
- $6.25BMarket Cap
- -Volume
- Consumer StaplesSector
- $33.7652W High
- $20.0052W Low
- -Typical Hold Time
- $12.99BEnterprise Value
- 4.77%Div Yield
- -Trading Activity
Track Campbell Soup Co. (CPB) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Campbell Soup Co. has traded between a low of $20 and a high of $33.76, highlighting its annual price range. Buy and sell Campbell Soup Co. shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About Campbell Soup Co.
With a history that dates back around 150 years, Campbell Soup is now a leading manufacturer and marketer of branded convenience food products, most notably soup. The firm's product assortment includes well-known brands like Campbell's, Pace, Prego, Swanson, V8, and Pepperidge Farm. Following the sale of its international snacking operations, which wrapped in calendar 2019, the firm derives nearly all of its sales from its home turf. Campbell has made a handful of acquisitions to reshape its product mix the past few years, including the tie-up with Snyder's-Lance (completed in March 2018), which enhances its exposure to the faster-growing on-trend snack food aisle, complementing its Pepperidge Farm lineup.
Most Recent News
Gen Digital COO sells 28,248 shares, signaling insider stock movement.
The Chief Operating Officer of Gen Digital sold 28,248 shares recently. This insider sale could indicate a personal financial decision or a strategic move, which investors might watch closely for signals about the company's outlook. While such sales ...

Kroger Q2 EPS beats estimates but revenue slightly misses; sales outlook lowered due to economic challenges
Kroger reported Q2 earnings with an EPS of $1.09, beating analyst expectations of $1.06 and showing 5% growth. Quarterly revenue was $34.62 billion, just below the $34.64 billion consensus but up from last year. The company lowered its full-year same...

Merck prepares for KEYTRUDA exclusivity loss, shares dip but monthly gains strong, earnings expected soon.
Merck & Co. is investing in new products and research to sustain growth as its key cancer drug, KEYTRUDA, nears loss of market exclusivity. Despite a recent 1.91% daily stock drop to $144.71, Merck's shares gained nearly 11% over the past month, outp...

People also bought
Frequently Asked Questions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.